Cited by 7,449Lipoproteins and Cardiovascular HealthAcute Myocardial Infarction ResearchCancer, Lipids, and Metabolism

The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.

Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia

Open access

Shepherd, James, Cobbe, Stuart M., Ford, Ian, Isles, Christopher G., Lorimer, A. Ross, Macfarlane, Peter W., McKillop, James H., Packard, Christopher J.·1995·New England Journal of Medicine

DOI 10.1056/nejm199511163332001

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: Lowering the blood cholesterol level may reduce the risk of coronary heart disease. This double-blind study was designed to determine whether the administration of pravastatin to men with hypercholesterolemia and no history of myocardial infarction reduced the combined incidence of nonfatal myocardial infarction and death from coronary heart disease. METHODS: We randomly assigned 6595 men, 45 to 64 years of age, with a mean (+/- SD) plasma cholesterol level of 272 +/- 23 mg per deciliter (7.0 +/- 0.6 mmol per liter) to receive pravastatin (40 mg each evening) or placebo. The average follow-up period was 4.9 years. Medical records, electrocardiographic recordings, and the national death registry were used to determine the clinical end points. RESULTS: Pravastatin lowered plasma cholesterol levels by 20 percent and low-density-lipoprotein cholesterol levels by 26 percent, whereas there was no change with placebo. There were 248 definite coronary events (specified as nonfatal myocardial infarction or death from coronary heart disease) in the placebo group, and 174 in the pravastatin group (relative reduction in risk with pravastatin, 31 percent; 95 percent confidence interval, 17 to 43 percent; P < 0.001). There were similar reductions in the risk of definite nonfatal myocardial infarctions (31 percent reduction, P < 0.001), death from coronary heart disease (definite cases alone: 28 percent reduction, P = 0.13; definite plus suspected cases: 33 percent reduction, P = 0.042), and death from all cardiovascular causes (32 percent reduction, P = 0.033). There was no excess of deaths from noncardiovascular causes in the pravastatin group. We observed a 22 percent reduction in the risk of death from any cause in the pravastatin group (95 percent confidence interval, 0 to 40 percent; P = 0.051). CONCLUSIONS: Treatment with pravastatin significantly reduced the incidence of myocardial infarction and death from cardiovascular causes without adversely affecting the risk of death from noncardiovascular causes in men with moderate hypercholesterolemia and no history of myocardial infarction.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1056/nejm199511163332001

Cites

26 of 26 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II)
Grundy, S. M., Bilheimer, D. W., Chait, A., Clark, L. T., Denke, M. A., Havel, R. J., Hazzard, W. R., Hulley, S. B., Hunninghake, D. B., Kreisberg, R. A., et al. (1993) · JAMA · doi:10.1001/jama.269.23.3015 · Cited by 27,944
Helsinki Heart Study: Primary-Prevention Trial with Gemfibrozil in Middle-Aged Men with Dyslipidemia
Frick, M. H., Elo, O., Haapa, K., Heinonen, O. P., Heinsalmi, P., Helo, P., Huttunen, J. K., Kaitaniemi, P., Koskinen, P., Manninen, V., et al. (1987) · New England Journal of Medicine · doi:10.1056/nejm198711123172001 · Cited by 3,881
A Multiple Testing Procedure for Clinical Trials
O'Brien, P. C., & Fleming, T. R. (1979) · Biometrics · doi:10.2307/2530245 · Cited by 3,311
The Lipid Research Clinics Coronary Primary Prevention Trial Results: I. Reduction in Incidence of Coronary Heart Disease
(1984) · JAMA · doi:10.1001/jama.1984.03340270029025 · Cited by 2,747
MRC trial of treatment of mild hypertension: principal results. Medical Research Council Working Party.
(1985) · BMJ · doi:10.1136/bmj.291.6488.97 · Cited by 1,491
Modelling Survival Data in Medical Research
Collett, D. (1994) · Springer eBooks · doi:10.1007/978-1-4899-3115-3 · Cited by 1,064
A co-operative trial in the primary prevention of ischaemic heart disease using clofibrate. Report from the Committee of Principal Investigators.
Oliver, M., Heady, J., Morris, J. N., Cooper, J., Geizerova, H., Gyárfás, I., Green, K., Strasser, T., Macfie, W. G., Scott, E., et al. (1978) · Heart · doi:10.1136/hrt.40.10.1069 · Cited by 1,047
Modelling Survival Data in Medical Research.
McLachlan, G. J., & Collett, D. (1994) · Biometrics · doi:10.2307/2533471 · Cited by 1,023
Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS).
Jukema, J., Bruschke, A. V., van Boven, A. J., Reiber, J., Bal, E., Zwinderman, A., Jansen, H., Boerma, G., van Rappard, F. M., & Kong, L. I. (1995) · Circulation · doi:10.1161/01.cir.91.10.2528 · Cited by 911
Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group.
Furberg, C. D., Adams, H. P., Applegate, W. B., Byington, R. P., Espeland, M. A., Hartwell, T., Hunninghake, D. B., Lefkowitz, D. S., Probstfield, J. L., & Riley, W. A. (1994) · Circulation · doi:10.1161/01.cir.90.4.1679 · Cited by 865

Show all 26 references

Research works printed but not linked: 4

10.1001/jama.251.3.351 · DOI · Paper page
1994, Lancet, 344, 1383
1992, Nutr Metab Cardiovasc Dis, 2, 113
Macfarlane PW, 1990, Eur Heart J, 11, 411

Sorted by citations

Items 601–700 of 1,060

Exercise reduces plasma levels of the chemokines MCP-1 and IL-8 in subjects with the metabolic syndrome
Trøseid, M. (2004) · European Heart Journal · doi:10.1016/j.ehj.2003.12.006 · Cited by 188
The sirtuin family members SIRT1, SIRT3 and SIRT6: Their role in vascular biology and atherogenesis
Sosnowska, B., Mazidi, M., Penson, P. E., Gluba-Brzózka, A., Rysz, J., & Banach, M. (2017) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2017.08.027 · Cited by 188
Squalene epoxidase as hypocholesterolemic drug target revisited
Chugh, A. (2002) · Progress in Lipid Research · doi:10.1016/s0163-7827(02)00029-2 · Cited by 188
Surrogate End Points, Health Outcomes, and the Drug-Approval Process for the Treatment of Risk Factors for Cardiovascular Disease
Psaty, B. M. (1999) · JAMA · doi:10.1001/jama.282.8.786 · Cited by 187
HMG-CoA Reductase Inhibitor Modulates Monocyte–Endothelial Cell Interaction Under Physiological Flow Conditions In Vitro
Yoshida, M., Sawada, T., Ishii, H., Gerszten, R. E., Rosenzweig, A., Gimbrone, M. A., Yasukochi, Y., & Numano, F. (2001) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/hq0701.092143 · Cited by 187
Recommendations for the management and treatment of dyslipidemia. Report of the Working Group on Hypercholesterolemia and Other Dyslipidemias.
FODOR, J. G., Frohlich, J., Genest, J. J., & McPherson, P. R. (2000) · Europe PMC (PubMed Central) · Cited by 185
Innate and Adaptive Inflammation as a Therapeutic Target in Vascular Disease
Tousoulis, D., Psarros, C., Demosthenous, M., Patel, R., Antoniades, C., & Stefanadis, C. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.01.054 · Cited by 187
Differing effect of statins on insulin sensitivity in non-diabetics: A systematic review and meta-analysis
Baker, W. L., Talati, R., White, C. M., & Coleman, C. I. (2009) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2009.10.008 · Cited by 188
Hepatitis C Virus Infection and Its Clearance Alter Circulating Lipids
Corey, K. E., Kane, E. M., Munroe, C. A., Barlow, L. L., Zheng, H., & Chung, R. T. (2009) · Hepatology · doi:10.1002/hep.23219 · Cited by 186
Patient, Physician, and Payment Predictors of Statin Adherence
Chan, D. C., Shrank, W. H., Cutler, D., Jan, S., Fischer, M. A., Liu, J., Avorn, J., Solomon, D. H., Brookhart, M. A., & Choudhry, N. K. (2010) · Medical Care · doi:10.1097/mlr.0b013e3181c132ad · Cited by 184
Beyond lipid-lowering: effects of statins on endothelial nitric oxide
Laufs, U. (2003) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-002-0556-0 · Cited by 185
Task force 1. Pathogenesis of coronary disease: The biologic role of risk factors
Fuster, V., Gotto, A. M., Libby, P., Loscalzo, J., & McGill, H. C. (1996) · Journal of the American College of Cardiology · doi:10.1016/0735-1097(96)00014-9 · Cited by 190
A multicenter, double-blind, one-year study comparing safety and efficacy of atorvastatin versus simvastatin in patients witb hypercholesterolemia
Dart, A. M., Jerums, G., Nicholson, G. C., dʼEmden, M. C., Hamilton‐Craig, I. R., Tallis, G. A., Best, J. D., West, M., SULLIVAN, D. R., Braes, P., et al. (1997) · The American Journal of Cardiology · doi:10.1016/s0002-9149(97)00280-4 · Cited by 186
Low-Density Lipoprotein Cholesterol Lowering for the Primary Prevention of Cardiovascular Disease Among Men With Primary Elevations of Low-Density Lipoprotein Cholesterol Levels of 190 mg/dL or Above: Analyses From the WOSCOPS (West of Scotland Coronary Prevention Study) 5-Year Randomized Trial and 20-Year Observational Follow-Up
Vallejo-Vaz, A. J., Robertson, M., Catapano, A. L., Watts, G. F., Kastelein, J. J., Packard, C. J., Ford, I., & Ray, K. K. (2017) · Circulation · doi:10.1161/circulationaha.117.027966 · Cited by 185
Self-citation
Association between Multidisciplinary Care and Survival for Elderly Patients with Chronic Kidney Disease
Hemmelgarn, B. R., Manns, B., Zhang, J., Tonelli, M. A., Klarenbach, S. W., Walsh, M. W., & Culleton, B. F. (2007) · Journal of the American Society of Nephrology · doi:10.1681/asn.2006080860 · Cited by 182
Pleiotropic effects of HMG-CoA reductase inhibitors
Werner, N., Nickenig, G., & Laufs, U. (2002) · Basic Research in Cardiology · doi:10.1007/s003950200000 · Cited by 186
Effects of Statins on Nonlipid Serum Markers Associated with Cardiovascular Disease
Balk, E. M., Lau, J., Goudas, L. C., Jordan, H. S., Kupelnick, B., Kim, L. U., & Karas, R. H. (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-139-8-200310210-00011 · Cited by 187
Plant sterols and cardiovascular disease: a systematic review and meta-analysis†
Genser, B., Silbernagel, G., De Backer, G., Bruckert, E., Carmena, R., Chapman, M. J., Deanfield, J., Descamps, O. S., Rietzschel, E. R., Dias, K. C., et al. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehr441 · Cited by 209
Efficacy of High-Dose Atorvastatin Loading Before Primary Percutaneous Coronary Intervention in ST-Segment Elevation Myocardial Infarction
Kim, J.-S., Kim, J., Choi, D., Lee, C. J., Lee, S. H., Ko, Y.-G., Hong, M.-K., Kim, B.-K., Oh, S. J., Jeon, D. W., et al. (2010) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2009.11.021 · Cited by 183
Plasma LDL and HDL Cholesterol and Oxidized LDL Concentrations Are Altered in Normo- and Hypercholesterolemic Humans after Intake of Different Levels of Cocoa Powder
Baba, S., Natsume, M., Yasuda, A., Nakamura, Y., Tamura, T., Osakabe, N., Kanegae, M., & Kondo, K. N. (2007) · Journal of Nutrition · doi:10.1093/jn/137.6.1436 · Cited by 183
ACC/AHA/ESC 2006 Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death—Executive Summary
Zipes, D. P., Camm, A. J., Borggrefe, M., Buxton, A. E., CHAITMAN, B. R., FROMER, M. A., Gregoratos, G., Klein, G. J., Myerburg, R. J., Quiñones, M. A., et al. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.07.008 · Cited by 184
Design and Baseline Characteristics of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Study
Amarenco, P., Bogousslavsky, J., Callahan, A., Goldstein, L. B., Hennerici, M. G., Sillsen, H., Welch, M. A., & Zivin, J. A. (2003) · Cerebrovascular Diseases · doi:10.1159/000072562 · Cited by 184
Statin Therapy in Stroke Prevention: A Meta-analysis Involving 121,000 Patients
O’Regan, C., Wu, P., Arora, P., Perri, D., & Mills, E. J. (2008) · The American Journal of Medicine · doi:10.1016/j.amjmed.2007.06.033 · Cited by 182
Simvastatin Therapy Reduces Prooxidant‐Antioxidant Balance: Results of a Placebo‐Controlled Cross‐Over Trial
Parizadeh, S. M. R., Azarpazhooh, M. R., Moohebati, M., Nematy, M., Ghayour‐Mobarhan, M., Tavallaie, S., Rahsepar, A. A., Amini, M., Sahebkar, A., Mohammadi, M., et al. (2011) · Lipids · doi:10.1007/s11745-010-3517-x · Cited by 182
Economics notes: Opportunity cost
Palmer, S., & Raftery, J. P. (1999) · BMJ · doi:10.1136/bmj.318.7197.1551 · Cited by 195
Progressive coronary calcification despite intensive lipid-lowering treatment: a randomised controlled trial
Houslay, E. S., Cowell, S. J., Prescott, R. J., Reid, J. H., Burton, J., Northridge, D. B., Boon, N. A., & Newby, D. E. (2006) · Heart · doi:10.1136/hrt.2005.080929 · Cited by 182
Lipoprotein atherogenicity: an overview of current mechanisms
Griffin, B. A. (1999) · Proceedings of The Nutrition Society · doi:10.1079/pns19990022 · Cited by 182
Statins and cardioprotection — More than just lipid lowering?
Ludman, A. J., Venugopal, V., Yellon, D. M., & Hausenloy, D. J. (2009) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2009.01.002 · Cited by 182
Pleiotropic effects of statins
Vasnawala, H., Kavalipati, N., Shah, J., & Ramakrishan, A. (2015) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/2230-8210.163106 · Cited by 189
Comparative Tolerability of the HMG-CoA Reductase Inhibitors
Farmer, J. A., & Torre‐Amione, G. (2000) · Drug Safety · doi:10.2165/00002018-200023030-00003 · Cited by 181
Pravastatin in patients with nonalcoholic steatohepatitis: results of a pilot study
Rallidis, L. S., Drakoulis, C., & Parasi, A. S. (2004) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2004.01.008 · Cited by 182
C-reactive protein and interleukin-6 in vascular disease
Rattazzi, M., Puato, M., Faggin, E., Bertipaglia, B., Zambon, A., & Pauletto, P. (2003) · Journal of Hypertension · doi:10.1097/00004872-200310000-00002 · Cited by 180
Treating patients with documented atherosclerosis to national cholesterol education program-recommended low-density-lipoprotein cholesterol goals with atorvastatin, fluvastatin, lovastatin and simvastatin
Brown, A. S., Bakker-Arkema, R. G., Yellen, L. G., et al. (1998) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(98)00300-3 · Cited by 181
Lowering blood homocysteine with folic acid based supplements: meta-analysis of randomised trials. Homocysteine Lowering Trialists' Collaboration.
Collaboration, H. L. T. (1998) · PubMed Central · Cited by 181
Cardiovascular risk in chronic obstructive pulmonary disease
Maclay, J. D., McAllister, D., & MacNee, W. (2007) · Respirology · doi:10.1111/j.1440-1843.2007.01136.x · Cited by 180
Tackling ischaemic heart disease in rheumatoid arthritis
Kitas, G. D. (2003) · British journal of rheumatology · doi:10.1093/rheumatology/keg175 · Cited by 180
Pravastatin therapy in hyperlipidemia: effects on thrombus formation and the systemic hemostatic profile
Dangas, G., Badimón, J. J., Smith, D. A., Unger, A. H., Levine, D., Shao, J. H., Meraj, P., Fier, C. M., Fallon, J. T., & Ambrose, J. A. (1999) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(99)00018-2 · Cited by 180
A multicenter, randomized, double-blind, placebo-controlled, factorial design study to evaluate the lipid-altering efficacy and safety profile of the ezetimibe/simvastatin tablet compared with ezetimibe and simvastatin monotherapy in patients with primary hypercholesterolemia
Bays, H. E., Ose, L., Fraser, N., Tribble, D. L., Quinto, K., Reyes, R., Johnson‐Levonas, A. O., Sapre, A., & Donahue, S. R. (2004) · Clinical Therapeutics · doi:10.1016/j.clinthera.2004.11.016 · Cited by 178
Potential therapeutic role for statins in respiratory disease
Hothersall, E. J. (2006) · Thorax · doi:10.1136/thx.2005.057976 · Cited by 178
Preventing Coronary Artery Disease by Lowering Cholesterol Levels
Steinberg, D. H., & Gotto, A. M. (1999) · JAMA · doi:10.1001/jama.282.21.2043 · Cited by 178
Lipoprotein Lp(a) Excess and Coronary Heart Disease
Stein, J. H. (1997) · Archives of Internal Medicine · doi:10.1001/archinte.1997.00440320040005 · Cited by 178
Rapid Effect of 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibition on Coronary Endothelial Function
Wassmann, S., Faul, A., Hennen, B., Scheller, B., Böhm, M., & Nickenig, G. (2003) · Circulation Research · doi:10.1161/01.res.0000099503.13312.7b · Cited by 177
Nanoparticle-Mediated Delivery of Pitavastatin Inhibits Atherosclerotic Plaque Destabilization/Rupture in Mice by Regulating the Recruitment of Inflammatory Monocytes
Katsuki, S., Matoba, T., Nakashiro, S., Sato, K., Koga, J.-I., Nakano, K., Nakano, Y., Egusa, S., Sunagawa, K., & Egashira, K. (2014) · Circulation · doi:10.1161/circulationaha.113.002870 · Cited by 179
The Severe Hypercholesterolemia Phenotype
Sniderman, A. D., Tsimikas, S., & Fazio, S. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.01.060 · Cited by 180
CP-346086
Chandler, C. E., Wilder, D. E., Pettini, J. L., Savoy, Y. E., Petras, S. F., Chang, G., Vincent, J., & Harwood, H. J. (2003) · Journal of Lipid Research · doi:10.1194/jlr.m300094-jlr200 · Cited by 177
Effects of Statins on High-Density Lipoproteins: A Potential Contribution to Cardiovascular Benefit
McTaggart, F., & Jones, P. J. H. (2008) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-008-6113-z · Cited by 186
Users' Guides to the Medical Literature
McAlister, F. A., Laupacis, A., Wells, G. A., Sackett, D. L., & for the Evidence-Based Medicine Working Group (1999) · JAMA · doi:10.1001/jama.282.14.1371 · Cited by 175
Tendinous disorders attributed to statins: A study on ninety‐six spontaneous reports in the period 1990–2005 and review of the literature
Marié, I., Delafenêtre, H., Massy, N., Thuillez, C., & Noblet, C. (2008) · Arthritis Care & Research · doi:10.1002/art.23309 · Cited by 175
Effect of statin therapy on colorectal cancer
Bardou, M., Barkun, A. N., & Martel, M. (2010) · Gut · doi:10.1136/gut.2009.190900 · Cited by 182
A Comparison of the Framingham Risk Index, Coronary Artery Calcification, and Culprit Plaque Morphology in Sudden Cardiac Death
Taylor, A. J., BURKE, A. P., O’Malley, P. G., Farb, A. A., Malcom, G. T., Smialek, J. E., & Virmani, R. (2000) · Circulation · doi:10.1161/01.cir.101.11.1243 · Cited by 176
Cholesterol and atherosclerosis
Libby, P. (2000) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/s1388-1981(00)00161-x · Cited by 183
Cell and molecular biology of the assembly and secretion of apolipoprotein B-containing lipoproteins by the liver
Davis, R. A. (1999) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/s1388-1981(99)00083-9 · Cited by 175
Discontinuation of Statin Therapy and Clinical Outcome After Ischemic Stroke
Colivicchi, F., Bassi, A., Santini, M., & Caltagirone, C. (2007) · Stroke · doi:10.1161/strokeaha.107.487017 · Cited by 174
Naringin Has an Antiatherogenic Effect With the Inhibition of Intercellular Adhesion Molecule-1 in Hypercholesterolemic Rabbits
良一, 橋., Kim, H.-S., Jeong, T.-S., Bok, S.-H., & Park, Y.-B. (2001) · Journal of Cardiovascular Pharmacology · doi:10.1097/00005344-200112000-00017 · Cited by 175
Coaching patients with coronary heart disease to achieve the target cholesterol:A method to bridge the gap between evidence-based medicine and the “real world”—randomized controlled trial
Vale, M., Jelinek, M. V., Best, J. D., & Santamaria, J. D. (2002) · Journal of Clinical Epidemiology · doi:10.1016/s0895-4356(01)00460-7 · Cited by 169
Why all randomised controlled trials produce biased results
Krauß, A. (2018) · Annals of Medicine · doi:10.1080/07853890.2018.1453233 · Cited by 187
The interaction of diltiazem with lovastatin and pravastatin*
Azie, N. E., Brater, D. C., Becker, P., Jones, D. R., & Hall, S. D. (1998) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(98)90067-4 · Cited by 173
Does statin therapy initiation increase the risk for myopathy? An observational study of 32,225 diabetic and nondiabetic patients
Nichols, G. A., & Koro, C. E. (2007) · Clinical Therapeutics · doi:10.1016/j.clinthera.2007.08.022 · Cited by 173
Dietary fats and cardiovascular disease: Putting together the pieces of a complicated puzzle
Michas, G., Micha, R., & Zampelas, A. (2014) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2014.03.013 · Cited by 178
Statin therapy is associated with improved patency of autogenous infrainguinal bypass grafts
Abbruzzese, T. A., Havens, J. M., Belkin, M., Donaldson, M. C., Whittemore, A. D., Liao, J. K., & Conte, M. S. (2004) · Journal of Vascular Surgery · doi:10.1016/j.jvs.2003.12.027 · Cited by 171
Seasonal variations in coronary heart disease
Pell, J. P. (1999) · QJM · doi:10.1093/qjmed/92.12.689 · Cited by 173
Prognostic value of the Framingham cardiovascular risk equation and the UKPDS risk engine for coronary heart disease in newly diagnosed Type 2 diabetes: results from a United Kingdom study
Guzder, R., Gatling, W., Mullee, M., Mehta, R. L., & Byrne, C. D. (2005) · Diabetic Medicine · doi:10.1111/j.1464-5491.2005.01494.x · Cited by 172
Statins and Cancer Risk: A Literature-Based Meta-Analysis and Meta-Regression Analysis of 35 Randomized Controlled Trials
Bonovas, S., Filioussi, K., Tsavaris, N., & Sitaras, N. M. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.3560 · Cited by 173
Safety of atorvastatin derived from analysis of 44 completed trials in 9,416 patients
Newman, C. B., Palmer, G., Silbershatz, H., & Szarek, M. J. (2003) · The American Journal of Cardiology · doi:10.1016/s0002-9149(03)00820-8 · Cited by 172
Interleukin-6 −174G>C Polymorphism and Risk of Coronary Heart Disease in West of Scotland Coronary Prevention Study (WOSCOPS)
Basso, F., Lowe, G. D. O., Rumley, A., McMahon, A. D., & Humphries, S. E. (2002) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000013283.84306.1a · Cited by 172
Targeting the mevalonate cascade as a new therapeutic approach in heart disease, cancer and pulmonary disease
Yeganeh, B., Wiecheć, E., Ande, S. R., Sharma, P. K., Moghadam, A. R., Post, M., Freed, D. H., Hashemi, M. M., Shojaei, S., Zeki, A. A., et al. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.02.007 · Cited by 169
Impact of telemonitoring at home on the management of elderly patients with congestive heart failure
Antonicelli, R., Testarmata, P., Spazzafumo, L., Gagliardi, C., Bilo, G., Valentini, M., Olivieri, F., & Parati, G. (2008) · Journal of Telemedicine and Telecare · doi:10.1258/jtt.2008.071213 · Cited by 174
Non-cardiovascular effects associated with statins
Desai, C. S., Martin, S. S., & Blumenthal, R. S. (2014) · BMJ · doi:10.1136/bmj.g3743 · Cited by 174
Alterations in cholesterol absorption/synthesis markers characterize Framingham Offspring Study participants with CHD
Matthan, N. R., Pencina, M. J., LaRocque, J. M., Jacques, P. F., D’Agostino, R. B., Schaefer, E. J., & Lichtenstein, A. H. (2009) · Journal of Lipid Research · doi:10.1194/jlr.p900039-jlr200 · Cited by 174
Association of the Trp719Arg Polymorphism in Kinesin-Like Protein 6 With Myocardial Infarction and Coronary Heart Disease in 2 Prospective Trials
Iakoubova, O. A., Tong, C. H., Rowland, C. M., Kirchgessner, T. G., Young, B. A., Arellano, A. R., Shiffman, D., Sabatine, M. S., Campos, H., Packard, C. J., et al. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.05.057 · Cited by 170
Prognostic and Therapeutic Implications of Statin and Aspirin Therapy in Individuals With Nonobstructive Coronary Artery Disease
Chow, B. J. W., Small, G. R., Yam, Y., Chen, L., McPherson, R., Achenbach, S. S., Al-Mallah, M. H., Berman, D. S., Budoff, M. J., Cademartiri, F., et al. (2015) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.114.304351 · Cited by 171
Cardioprotective Medication Is Associated With Improved Survival in Patients With Peripheral Arterial Disease
Feringa, H. H. H., van Waning, V. H., Bax, J. J., Elhendy, A., Boersma, E. H., Schouten, O., Galal, W., Vidaković, R., Tangelder, M. J. D., & Poldermans, D. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.09.074 · Cited by 172
Effects of Early Treatment With Statins on Short-term Clinical Outcomes in Acute Coronary Syndromes
Briel, M., Schwartz, G. G., Thompson, P. L., de Lemos, J. A., Blazing, M. A., van Es, G., Kayıkçıoğlu, M., Arntz, H.-R., den Hartog, F. R., Veeger, N. J. G. M., et al. (2006) · JAMA · doi:10.1001/jama.295.17.2046 · Cited by 169
Cholesterol in islet dysfunction and type 2 diabetes
Brunham, L. R., Kruit, J. K., Verchere, C. B., & Hayden, M. R. (2008) · Journal of Clinical Investigation · doi:10.1172/jci33296 · Cited by 158
Rosuvastatin in the Prevention of Stroke Among Men and Women With Elevated Levels of C-Reactive Protein
Everett, B. M., Glynn, R. J., MacFadyen, J. G., & Ridker, P. M. (2009) · Circulation · doi:10.1161/circulationaha.109.874834 · Cited by 168
Feedback and Hormonal Regulation of Hepatic 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase: The Concept of Cholesterol Buffering Capacity
Ness, G. C., & Chambers, C. M. (2000) · Proceedings of The Society for Experimental Biology and Medicine · doi:10.1046/j.1525-1373.2000.22359.x · Cited by 168
Treatment With Simvastatin Suppresses the Development of Experimental Abdominal Aortic Aneurysms in Normal and Hypercholesterolemic Mice
Steinmetz, E. F., Buckley, C., Shames, M. L., Ennis, T. L., VanVickle-Chavez, S. J., Mao, D., Goeddel, L. A., Hawkins, C. J., & Thompson, R. W. (2005) · Annals of Surgery · doi:10.1097/01.sla.0000150258.36236.e0 · Cited by 169
Mechanisms of Vascular Disease: A Reference Book for Vascular Specialists
Fitridge, R., & Thompson, M. M. (2011) · Cited by 168
Synthesis and Biological Activity of Methanesulfonamide Pyrimidine- and N-Methanesulfonyl Pyrrole-Substituted 3,5-Dihydroxy-6-heptenoates, a Novel Series of HMG-CoA Reductase Inhibitors
Watanabe, M., Koike, H., ISHIBA, T., et al. (1997) · Bioorganic & Medicinal Chemistry · doi:10.1016/s0968-0896(96)00248-9 · Cited by 167
The relationship between reduction in low-density lipoprotein cholesterol by statins and reduction in risk of cardiovascular outcomes: An updated meta-analysis
Delahoy, P. J., Magliano, D. J., Webb, K., Grobler, M. P., & Liew, D. (2009) · Clinical Therapeutics · doi:10.1016/j.clinthera.2009.02.017 · Cited by 169
Lipid responses to plant-sterol-enriched reduced-fat spreads incorporated into a National Cholesterol Education Program Step I diet
Maki, K. C., Davidson, M. H., Umporowicz, D. M., Schaefer, E. J., Dicklin, M. R., Ingram, K. A., Chen, S., McNamara, J. R., Gebhart, B. W., Ribaya‐Mercado, J. D., et al. (2001) · American Journal of Clinical Nutrition · doi:10.1093/ajcn/74.1.33 · Cited by 166
The effect of interventions to prevent cardiovascular disease in patients with type 2 diabetes mellitus
Huang, E. S., Meigs, J. B., & Singer, D. E. (2001) · The American Journal of Medicine · doi:10.1016/s0002-9343(01)00978-0 · Cited by 163
Sterol regulatory element binding proteins (SREBP)-1a and SREBP-2 are linked to the MAP-kinase cascade
Kotzka, J., Müller-Wieland, D., Roth, G., Kremer, L., Munck, M., Schürmann, S., Knebel, B., & Krone, W. (2000) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)32079-4 · Cited by 146
Columbia University's Informatics for Diabetes Education and Telemedicine (IDEATel) Project: Rationale and Design
Shea, S., Starren, J. B., Weinstock, R. S., Knudson, P. E., Teresi, J. A., Holmes, D., Palmas, W., Field, L., Goland, R., Tuck, C. H., et al. (2002) · Journal of the American Medical Informatics Association · doi:10.1136/jamia.2002.0090049 · Cited by 167
The atherogenic lipoprotein phenotype and vascular endothelial dysfunction
Sattar, N. A., Petrie, J. R., & Jaap, A. J. (1998) · Atherosclerosis · doi:10.1016/s0021-9150(98)00037-9 · Cited by 162
Treatment patterns and distribution of low-density lipoprotein cholesterol levels in treatment-eligible united states adults
Hoerger, T. J., BALA, M. M., Bray, J. W., Wilcosky, T. C., & LaRosa, J. C. (1998) · The American Journal of Cardiology · doi:10.1016/s0002-9149(98)00227-6 · Cited by 167
Targeting lipid-lowering drug therapy for primary prevention of coronary disease: an updated Sheffield table
Ramsay, L., Haq, I., Jackson, P., Yeo, W. W., Pickin, D. M., & Payne, J. N. (1996) · The Lancet · doi:10.1016/s0140-6736(96)05516-x · Cited by 167
Recent advances in pharmacotherapy for hypertriglyceridemia
Sahebkar, A., Chew, G. T., & Watts, G. F. (2014) · Progress in Lipid Research · doi:10.1016/j.plipres.2014.07.002 · Cited by 166
Fibrates are an essential part of modern anti-dyslipidemic arsenal: spotlight on atherogenic dyslipidemia and residual risk reduction
Tenenbaum, A., & Fisman, E. Z. (2012) · Cardiovascular Diabetology · doi:10.1186/1475-2840-11-125 · Cited by 172
Number Needed to Treat With Rosuvastatin to Prevent First Cardiovascular Events and Death Among Men and Women With Low Low-Density Lipoprotein Cholesterol and Elevated High-Sensitivity C-Reactive Protein
Ridker, P. M., MacFadyen, J. G., Fonseca, F. A. H., Genest, J. J., Gotto, A. M., Kastelein, J. J. P., Köenig, W., Libby, P., Lorenzatti, A. J., Nordestgaard, B. G., et al. (2009) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.109.848473 · Cited by 163
Low-Density Lipoprotein-Dependent and -Independent Effects of Cholesterol-Lowering Therapies on C-Reactive Protein
Kinlay, S. (2007) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.01.083 · Cited by 164
Improvement in Japanese Clinical Laboratory Measurements of Total Cholesterol and HDL-cholesterol by the US Cholesterol Reference Method Laboratory Network
Nakamura, M., Sato, S., & Shimamoto, T. (2003) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.10.145 · Cited by 159
Simvastatin Preserves Coronary Endothelial Function in Hypercholesterolemia in the Absence of Lipid Lowering
Wilson, S. H., Simari, R. D., Best, P. J. M., Peterson, T. E., Lerman, L. O., Aviram, M., Nath, K. A., Holmes, D. R., & Lerman, A. (2001) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.21.1.122 · Cited by 166
Disposition of the Selective Cholesterol Absorption Inhibitor Ezetimibe in Healthy Male Subjects
Patrick, J. E., Kosoglou, T., Stauber, K. L., Alton, K. B., Maxwell, S. E., Zhu, Y., Statkevich, P., Iannucci, R., Chowdhury, S. K., Affrime, M. B., et al. (2002) · Drug Metabolism and Disposition · doi:10.1124/dmd.30.4.430 · Cited by 164
Medication-Attributed Adverse Effects in Placebo Groups: Implications for Assessment of Adverse Effects
Rief, W., Avorn, J., & Barsky, A. J. (2006) · Archives of Internal Medicine · doi:10.1001/archinte.166.2.155 · Cited by 167
Simvastatin Effects on Skeletal Muscle
Larsen, S., Stride, N., Hey-Mogensen, M., Hansen, C. N., Bang, L. E., Bundgaard, H., Nielsen, L. B., Helge, J. W., & Dela, F. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.09.036 · Cited by 165
Short-Term Treatment With Atorvastatin Reduces Platelet CD40 Ligand and Thrombin Generation in Hypercholesterolemic Patients
Sanguigni, V., Pignatelli, P., Lenti, L., Ferro, D., Bellia, A., Carnevale, R., Tesauro, M., Sorge, R. P., Lauro, R., & Violi, F. (2005) · Circulation · doi:10.1161/01.cir.0000153810.81187.7d · Cited by 166
Effects of HMG-CoA Reductase Inhibitors on Coagulation and Fibrinolysis Processes
Krysiak, R. G., Okopie, B., & Herman, Z. S. (2003) · Drugs · doi:10.2165/00003495-200363170-00005 · Cited by 165
Delayed Response of Myocardial Flow Reserve to Lipid-Lowering Therapy With Fluvastatin
Güthlin, M., Kasel, A. M., Coppenrath, K., Ziegler, S. I., Delius, W., & Schwaiger, M. (1999) · Circulation · doi:10.1161/01.cir.99.4.475 · Cited by 165
Rosuvastatin Reduces Atherosclerosis Development Beyond and Independent of Its Plasma Cholesterol–Lowering Effect in APOE*3-Leiden Transgenic Mice
Kleemann, R., Princen, H. M. G., EMEIS, J. J., Jukema, J. W., Fontijn, R. D., Horrevoets, A. J. G., Kooistra, T., & Havekes, L. M. (2003) · Circulation · doi:10.1161/01.cir.0000086460.55494.af · Cited by 165

Authors: Shepherd, J., Cobbe, S. M., Ford, I., Isles, C. G., Lorimer, A. R., Macfarlane, P. W., McKillop, J. H., & Packard, C. J.
Affiliations: Glasgow Royal Infirmary (GB)
University of Glasgow (GB)
NHS Dumfries and Galloway (GB)
ORCID: Ford, Ian
Macfarlane, Peter W.
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 1995-11-16
Volume: 333
Issue: 20
Pages: 1301-1308
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejm199511163332001
OpenAlex: W2155598961
Semantic Scholar: 1aa5f64bbe1d0c4c74fc3de7c89ac2dffb48630a
Cited by: 7,449
References: 26
Citations by year: 2026: 31 · 2025: 33 · 2024: 56 · 2023: 54 · 2022: 66 · 2021: 72 · 2020: 95 · 2019: 90 · 2018: 108 · 2017: 121 · 2016: 157 · 2015: 137 · 2014: 177 · 2013: 215 · 2012: 197
FWCI: 344.87
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
Funders: Bristol-Myers Squibb
Topics: Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
Keywords: pravastatin, hypercholesterolemia, coronary heart disease prevention, statins, LDL cholesterol lowering, nonfatal myocardial infarction, cardiovascular mortality, men, cholesterol-lowering therapy
MeSH terms: Anticholesteremic Agents, Cholesterol, Coronary Disease, Double-Blind Method, Humans, Hypercholesterolemia, Cholesterol, LDL, Male, Middle Aged, Myocardial Infarction, Neoplasms, Risk, Incidence, Survival Analysis, Pravastatin

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks